title: [Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
abstract: We report two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer. Case 1 was a 59-year-old man. We performed an operation for cancer of the rectum. At 2 years after the operation, he received mFOLFOX6 + bevacizumab therapy for a recurrence in the pelvis and lungs metastasis. After the 14th courses, He had a right shoulder pain and contrast enhanced computed tomography revealed deep vein thrombosis to the right arms. Case 2 was a 65-year-old man. We performed an operation for cancer of the rectum. At 6 months after the operation, he received mFOLFOX6 + bevacizumab therapy for lung metastases. After the 6th courses, contrast enhanced computed tomography revealed deep venous and pulmonary thrombosis for both sides, pulmonary thrombosis.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Otsuka Hospital.
authors.forename: Takashi
authors.initials: T
authors.lastname: Hosokawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Tokita
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Nishida
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Iwao
authors.forename: Haruya
authors.initials: H
authors.lastname: Koshiishi
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
authors.forename: Tsugumichi
authors.initials: T
authors.lastname: Koshinaga
mesh_terms: D000368:Aged; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011655:Pulmonary Embolism / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy; D020246:Venous Thrombosis / Q000139:chemically induced*
chemical_list: D043925:Angiogenesis Inducing Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil